Fig. 1: Treatment with BET inhibitor alters chromatin accessibility and mRNA expression levels in AML cells. | Blood Cancer Journal

Fig. 1: Treatment with BET inhibitor alters chromatin accessibility and mRNA expression levels in AML cells.

From: Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

Fig. 1

a AML SET2 cells were treated with BET inhibitor OTX015 for 16 h. Cells were harvested and ATAC-Seq analysis was performed. The total number of peaks gained or lost in OTX015-treated cells compared to untreated cells are shown. b Log2 fold-change in gained or lost peaks at the transcription start site or within 10 kb of the gene body of leukemia-relevant genes. c Transcription factor motifs increased in up (gained) peaks in OTX015-treated AML SET2 cells over control cells and the associated –log10 p value. d Relative fold-change in BET inhibitor-treated AML SET2 cells over control as determined by RNA-Seq analysis

Back to article page